Request Trial
shutterstock_311333621_flamingo_images
Flamingo Images / Shutterstock.com
22 December 2021PharmaChad Shear

A guide for life sciences entrepreneurs

The strength of a company’s IP is a central factor in determining its value, and perhaps nowhere is this more evident than in the life sciences industry. Because of the huge upfront expenditures required to develop products in the pharmaceutical, biotechnology, and other life sciences industries, a strong IP portfolio can be the difference between success and failure.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Pharma
Takeda sees off UK challenge to Elvanse SPC
28 September 2026   Can a drug’s ‘inactive’ precursor qualify for a multi-million pound patent extension? The UK High Court has just delivered a ruling on Takeda's ADHD drug Elvanse, weighing regulatory precedent against a conflicting German decision.
Pharma
Mylan throws down new gauntlet in Novo Wegovy patent fight
25 September 2026   Another Wegovy patent has been drawn into the long-running dispute between Mylan and Novo Nordisk over proposed generic versions of the weight-loss drug.
Pharma
Novartis defeats Orange Book challenge but suffers EU setback
24 September 2026   An Entresto Orange Book listing has survived a challenge in the US, while two trademark disputes handed Novartis contrasting fortunes at a European court.


Editor's picks

Inside the deal boom: LSIPR’s five-part M&A series—all in one place
Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026

Editor's picks

Regulation & Industry
Inside the deal boom: LSIPR’s five-part M&A series—all in one place
17 September 2026
Biotech
Exelixis locks down cancer drug exclusivity until 2030 with Fed Circ win
1 September 2026
Regulation & Industry
The buyers' wishlist: What makes a life sciences deal stack up?
25 August 2026
MedTech
Abbott fends off Chinese rival’s patent challenge at UPC
18 August 2026
Regulation & Industry
Where Big Pharma is betting big in the M&A boom
29 July 2026
Regulation & Industry
Buying the brains: Why is Big Pharma shopping for innovation?
27 July 2026

More features

Takeda sees off UK challenge to Elvanse SPC
Mylan throws down new gauntlet in Novo Wegovy patent fight
Novartis defeats Orange Book challenge but suffers EU setback
US firm hires litigation pro whose clients include Pfizer, Medtronic
Behind the case: How Novartis defended its blockbuster Entresto in the UK
Leading European patent litigator to join Carpmaels & Ransford
Non-profit sues Cambrex over anticancer drug manufacturing trade secrets
Inside the deal boom: LSIPR’s five-part M&A series—all in one place